Tatiana McHardy
Institute of Cancer Research(GB)Cancer Research UK(GB)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Chemical Synthesis and Analysis, Biochemical and Molecular Research, Protein Kinase Regulation and GTPase Signaling, DNA Repair Mechanisms
Most-Cited Works
- → Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration(2008)99 cited
- → A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera(2007)89 cited
- → Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)(2010)83 cited
- → The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma(2015)68 cited
- → Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design(2007)65 cited
- → Molecular mechanisms of human IRE1 activation through dimerization and ligand binding(2015)55 cited
- → Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening(2009)41 cited
- → Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)(2016)37 cited
- → Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors(2012)30 cited
- → Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases(2010)29 cited